Liu Li, Xie Xiao-Tian
Department of Pediatrics, Tongji Hospital, Tongji University, Shanghai 200065, China.
Zhongguo Dang Dai Er Ke Za Zhi. 2014 Feb;16(2):155-60.
The chemotherapy agent L-asparaginase (L-asp) has been an important part of acute lymphoblastic leukemia therapy for over 30 years. It is evident that L-asp has a long-term curative effect. However, L-asp is associated with high incidence of adverse reactions. This has prompted the development of pegylated asparaginase (PEG-asp), which has undergone extensive testing. Apparently, PEG-asp has a prolonged half-life with a better tolerance profile while retaining the antileukemic effect. In this review, we attempt to outline the history of clinical application of L-asp, the pharmacological and clinical potential of various preparations of L-asp, the development of PEG-asp, and the clinical application and adverse events of PEG-asp. The literatures reviewed in this article is collected through online search of the major databases both in English and Chinese.
化疗药物L-天冬酰胺酶（L-asp）30多年来一直是急性淋巴细胞白血病治疗的重要组成部分。显然，L-asp具有长期治愈效果。然而，L-asp与不良反应的高发生率相关。这促使了聚乙二醇化天冬酰胺酶（PEG-asp）的研发，其已进行了广泛测试。显然，PEG-asp半衰期延长，耐受性更好，同时保留了抗白血病作用。在本综述中，我们试图概述L-asp的临床应用历史、L-asp各种制剂的药理和临床潜力、PEG-asp的研发以及PEG-asp的临床应用和不良事件。本文综述的文献通过在线检索中英文主要数据库收集。
